Actithera applies medicinal chemistry and radiochemistry to develop next-generation radioligand therapies (RLTs) using a proprietary three-pillar discovery platform. The platform combines rational drug design, first-in-class covalent targeting strategies, and two additional proprietary approaches to optimize tumor residence time while ensuring rapid systemic clearance. Its work on fibroblast activation protein (FAP) produced a FAP-directed RLT development candidate with an optimal pharmacokinetic profile and tumor specificity. The company plans to advance its lead FAP asset into clinical development across multiple indications and to expand its preclinical pipeline. Actithera was founded in 2021 and is headquartered in Oslo, Norway and Cambridge, Massachusetts.

Total raised

$76M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2025